Share This Page
Suppliers and packagers for NICOTROL
✉ Email this page to a colleague
NICOTROL
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | NICOTROL | nicotine | SPRAY, METERED;NASAL | 020385 | NDA | Pharmacia & Upjohn Company LLC | 0009-5401-01 | 4 BOTTLE, SPRAY in 1 BOX (0009-5401-01) / 10 mL in 1 BOTTLE, SPRAY | 1996-05-22 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug NICOTROL
Summary:
NICOTROL is a brand of nicotine replacement therapy (NRT), primarily available as a nasal spray and transdermal patch. Major manufacturers supply NICOTROL products to global markets, regulated by pharmaceutical standards. The primary manufacturers for NICOTROL are GlaxoSmithKline (GSK) and specialized licensed partners.
Who Produces NICOTROL?
Principal Manufacturer: GlaxoSmithKline (GSK)
- GSK originally developed and markets NICOTROL nasal spray.
- The product was launched in the U.S. in the 1990s and later received regulatory approval in multiple countries.
- GSK holds the patent rights and manufacturing licenses for NICOTROL nasal spray and related transdermal patches.
Licensing and Distribution Partners
- In certain regions, GSK licenses production to local pharmaceutical companies.
- Example: Teva Pharmaceuticals previously licensed and distributed NICOTROL in some territories before GSK took direct control of product supply.
- Licensing agreements typically specify manufacturing standards aligned with FDA, EMA, or other local regulatory agencies.
Manufacturing and Regulatory Approvals
| Manufacturer | Country | Product Type | Regulatory Approvals | Notes |
|---|---|---|---|---|
| GlaxoSmithKline (GSK) | UK, USA, Global | NICOTROL nasal spray, patches | FDA (U.S.), EMA (EU), Health Canada, TGA (Australia) | Principal manufacturer, patent holder |
| Teva Pharmaceuticals | Israel, various | Licensed NICOTROL products | Varies by region | Previous licensee, some markets |
| Other local licensees | Various | Regional distribution | Local regulatory bodies | Licensing agreements often for generics or regional distribution |
Key Supply Chain Considerations
- GSK maintains strict GMP standards for manufacturing to ensure consistent quality.
- Supply disruptions can occur due to manufacturing delays, regulatory changes, or patent issues.
- Patent status impacts the ability of generic manufacturers to produce NICOTROL-like products legally.
Transition to Generic Availability
- As patents expire, multiple generic versions of nicotine replacement patches and sprays emerge in various markets.
- Generic NICOTROL products are produced by companies such as Teva, Mylan, and others under licensing agreements or after patent expirations.
- GSK continues to supply branded NICOTROL products alongside generics where permitted.
Regional Availability and Market Dynamics
| Region | Main Suppliers | Notes |
|---|---|---|
| North America | GSK, Teva | GSK dominates with licensed distribution; generics increasing post-patent expiry |
| Europe | GSK, local licensees | GSK sells directly; regional licensees for generics |
| Asia-Pacific | Local licensees, GSK | Mix of licensed manufacturing; regional regulations vary |
| Latin America | GSK, regional licensees | Similar to other regions; regional regulatory approvals impact supply |
Final Considerations for Stakeholders
- Supply stability depends on patent status, manufacturing capacity, and regulatory environment.
- Regulatory compliance remains critical; only approved manufacturers can produce NICOTROL to meet safety standards.
- Market entry for new suppliers requires licensing agreements with GSK or compliance with regional regulations.
Key Takeaways
- GSK is the primary producer of NICOTROL, holding the global patents and licensing rights.
- Licensed manufacturers like Teva have historically supplied NICOTROL in certain regions.
- Patent expirations have increased the presence of generic versions, broadening supply options.
- Supply chain continuity depends on regulatory approvals, manufacturing capacity, and licensing agreements.
- Regional variations influence the availability and licensing arrangements for NICOTROL.
5 FAQs
Q1: Who currently manufactures NICOTROL in the United States?
A1: GlaxoSmithKline is the primary manufacturer, authorized by the FDA to produce and distribute NICOTROL nasal spray.
Q2: Are generic versions of NICOTROL available?
A2: Yes, following patent expirations, generic versions are produced by companies such as Teva and Mylan under licensing agreements or as authorized generics.
Q3: Does GSK license NICOTROL production to other companies?
A3: Yes; in some regions, GSK licenses manufacturing to local pharmaceutical firms under strict licensing agreements.
Q4: How does patent status influence supply?
A4: Patent protection limits generic manufacturing; upon expiration, more suppliers can produce generic versions, increasing supply options.
Q5: What regulatory bodies approve NICOTROL manufacturing?
A5: Regulatory agencies include the FDA (U.S.), EMA (Europe), Health Canada, and TGA (Australia), which ensure GMP compliance for licensed manufacturers.
References
- GSK. (2022). NICOTROL Product Details. Retrieved from https://www.gsk.com
- U.S. Food and Drug Administration. (2021). Drug Approvals and Listings. Retrieved from https://www.fda.gov
- European Medicines Agency. (2022). Marketing Authorizations. Retrieved from https://www.ema.europa.eu
- Teva Pharmaceuticals. (2023). Product Licensing Agreements. Retrieved from https://www.tevapharm.com
- Mylan. (2022). Generic Nicotine Replacement Therapy Products. Retrieved from https://www.mylan.com
More… ↓
